Abstract P238: Effect of Zamicastat in Chronic Treatment on Right Ventricle Pressure Overload in the Rat Monocrotaline Lung Injury Model of Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is defined, foremost, as a plexogenic arteriopathy with subtotal luminal obliteration that increases pulmonary vascular resistance and imposes a hemodynamic stress on the right ventricle (RV) leading to RV hypertrophy and failure that contributes to premature death. There is experimental and clinical evidence that supports a relation between PAH and the sympathetic nervous system (SNS), indicating that PAH can be mediated, at least partly, by SNS hyperactivation. A strategy for the modulation of sympathetic nerve function is to reduce the biosynthesis of norepinephrine (NE) by inhibiting dopamine β-hydroxylase (DβH), the enzyme that catalyzes the conversion of dopamine (DA) to NE in sympathetic nerves. Here, we evaluated the effect of 18-day oral treatment with the DβH inhibitor zamicastat on RV pressure overload in the monocrotaline (MCT)-induced pulmonary hypertension (PH) model in the rat. MCT increased RV systolic pressure (54.7±2.9 vs 32.3±1.0 mmHg, p<0.0001), mean RV pressure (23.9±1.7 vs 16.6±1.1 mmHg, p<0.001), and decreased heart rate (240.0±5.9 vs 285.8±7.6 beats/min, p<0.0001) in vehicle-treated rats, as compared to pre-MCT values. Zamicastat treatment prevented the MCT-induced increase in mean RV pressure (change from baseline: +1.9±1.5 vs +7.4±1.8 mmHg, p<0.05). Likewise, the HR decrease was significantly attenuated in the zamicastat group as compared to the vehicle group (change from baseline: -14.3±9.7 vs -45.8±8.1 beats/min, p<0.05). Chronic zamicastat treatment decreased NE levels (480.5±43.9 vs 712.1±46.5 ng/mg protein, p<0.005) and increased DA levels (533.0±49.7 vs 12.3±2.3 ng/mg protein, p<0.0001) in adrenal gland homogenates of MCT-treated rats, as compared to vehicle group demonstrating robust inhibition of DβH. In conclusion, the DβH inhibitor zamicastat reverses heart rate and RV pressure changes, two hallmarks of PAH, in the rat MCT lung injury model.